Fluoroquinolone resistance in bacteremic and low risk febrile neutropenic patients with cancer

BACKGROUND: The low risk febrile neutropenic patients with Multinational Association for Supportive Care in Cancer (MASCC) score of more than 20 are recommended to be treated with fluoroquinolone-based oral treatment by the National Comprehensive Cancer Network (NCCN) guideline. This recommendation...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Sheng, Wang, Qing, Ling, Yun, Hu, Xichun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4326398/
https://www.ncbi.nlm.nih.gov/pubmed/25763661
http://dx.doi.org/10.1186/s12885-015-1063-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4326398/
https://www.ncbi.nlm.nih.gov/pubmed/25763661
http://dx.doi.org/10.1186/s12885-015-1063-x

Ejemplares similares